Arabic Arabic English English French French German German
dark

Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara®, in the United States. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nyxoah Appoints Rita Johnson-Mills to its Board of Directors

Next Post

AlzeCure’s ACD856 Demonstrates Good Tolerability in Phase I Clinical Trial and is Approved for Additional Doses

Related Posts
Total
0
Share